Compare Ishares Msci Italy ETF (EWI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Italy ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Ishares Msci Italy ETF trades at $60.54, while State Street SPDR S&P Biotech ETF trades at $152.02. The key difference: Ishares Msci Italy ETF is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals.
| EWI | XBI | |
|---|---|---|
Sector | Broad Market / Factor | Broad Market / Factor |
52-Week High | $61.14 | $164.28 |
52-Week Low | $47.75 | $85.16 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $155.19, down 0.23% on the day, with a bullish technical signal from moving averages. Recent news highlights strong biotech sector momentum, with the ETF gaining nearly 17% in a month (24/7 Wall Street, 2026-07-06). Analyst consensus is neutral with a single hold rating, while technical indicators show a neutral RSI and mixed ADX signals. Support is seen near $153, with resistance at $157.
The outlook for XBI is supported by sector strength and M&A activity, but high volatility and a neutral analyst stance suggest cautious optimism. Key risks include regulatory uncertainty and macroeconomic pressures, requiring careful risk management for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ishares Msci Italy ETF
EWI is a country-specific ETF that tracks the performance of the Italian equity market. It provides targeted access to large and mid-sized companies in Italy, with a heavy focus on the financial sector and holdings like UniCredit and Intesa Sanpaolo.
Read more on EWI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
